Zacks Research Weighs in on OPKO Health FY2027 Earnings

OPKO Health, Inc. (NASDAQ:OPK) – Analysts at Zacks Research issued their FY2027 earnings per share estimates for OPKO Health in a research report issued to clients and investors on Thursday, March 20th. Zacks Research analyst R. Department expects that the biotechnology company will earn ($0.09) per share for the year. The consensus estimate for OPKO Health’s current full-year earnings is ($0.25) per share.

Other research analysts also recently issued research reports about the stock. Barrington Research reaffirmed an “outperform” rating and issued a $2.25 price target on shares of OPKO Health in a research note on Wednesday, March 12th. HC Wainwright reaffirmed a “buy” rating and set a $3.00 target price on shares of OPKO Health in a research report on Wednesday, March 19th. Finally, StockNews.com raised shares of OPKO Health from a “sell” rating to a “hold” rating in a research note on Monday, March 3rd.

OPKO Health Stock Down 1.1 %

NASDAQ:OPK opened at $1.80 on Monday. The company has a market cap of $1.21 billion, a price-to-earnings ratio of -9.47 and a beta of 1.70. OPKO Health has a twelve month low of $0.92 and a twelve month high of $2.04. The company has a current ratio of 2.97, a quick ratio of 2.69 and a debt-to-equity ratio of 0.30. The stock has a fifty day simple moving average of $1.65 and a 200-day simple moving average of $1.57.

OPKO Health (NASDAQ:OPK) last posted its quarterly earnings data on Thursday, February 27th. The biotechnology company reported $0.01 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.09. The company had revenue of $183.60 million during the quarter, compared to analysts’ expectations of $155.42 million. OPKO Health had a negative return on equity of 9.76% and a negative net margin of 18.65%.

Insider Activity at OPKO Health

In other OPKO Health news, CEO Phillip Md Et Al Frost bought 500,000 shares of the company’s stock in a transaction on Wednesday, January 15th. The shares were bought at an average cost of $1.48 per share, for a total transaction of $740,000.00. Following the acquisition, the chief executive officer now directly owns 213,036,477 shares in the company, valued at approximately $315,293,985.96. The trade was a 0.24 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders bought 964,971 shares of company stock worth $1,493,692 over the last three months. 47.26% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. FMR LLC grew its holdings in OPKO Health by 103.6% during the 3rd quarter. FMR LLC now owns 21,795 shares of the biotechnology company’s stock worth $32,000 after acquiring an additional 11,089 shares in the last quarter. Wealth Enhancement Advisory Services LLC grew its holdings in OPKO Health by 75.3% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 28,908 shares of the biotechnology company’s stock worth $42,000 after acquiring an additional 12,417 shares in the last quarter. Orion Portfolio Solutions LLC bought a new position in OPKO Health during the 3rd quarter worth about $45,000. Cibc World Markets Corp bought a new position in OPKO Health during the 4th quarter worth about $45,000. Finally, Zacks Investment Management bought a new position in OPKO Health during the 4th quarter worth about $49,000. 64.63% of the stock is currently owned by institutional investors.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.